You are here

Article Text

Article menu

See original article:

Download PDFPDF

XML
Miscellaneous
Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

http://dx.doi.org/10.1136/jnnp-2013-307282corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 2014;85:1198–1208.

    For Figure 3 (A), the 95% CI values provided for the 3 Ponesimod groups below each percent (e.g., 10 mg shows 43% (0.34-0.95)) are not correct as the CI intervals belong to the treatment effect [ratio] and not percentage reduction. Instead, for Figure 3 (A), the graph should indicate the following: 10 mg: 43% (95% CI: 4.8-66.3), 20 mg: 83% (95% CI: 71.1-90.0), and 40mg: 77% (95% CI: 61.6-86.7).

    Figure legend should read as follows:

    Figure 3
    Figure 3

    (A) Cumulative number of new T1 Gd +lesions detected by magnetic resonance image scanning at weeks 12–24 (per-protocol analysis set). Graph shows mean+SE.SE The percentage reduction (95% CI) vs placebo is shown for each ponesimod treatment group. (B) Dose–response analysis for the cumulative number of new T1 Gd +lesions from week 12 to 24 (per-protocol analysis set). Black dots represent the mean value for each dose and grey dots represent the fitted models obtained in the bootstrap process. *p<0.05; **p<0.0001. T1 Gd+, T1-weighted gadolinium-enhanced.

    Linked Articles